The global mRNA synthesis raw materials market size is projected to reach USD 1.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.85% from 2024 to 2030. The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research. In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.
Furthermore, many major pharmaceutical firms have started working on mRNA-based therapeutics, including Novartis, Alexion, AstraZeneca, Pfizer, Sanofi Pasteur, and Shire. For instance, in January 2022, according to a development and option agreement between Pfizer Inc. and Acuitas Therapeutics, Pfizer will have the option to license Acuitas' LNP technology for up to 10 targets for the development of mRNA therapeutics & vaccines. Therefore, the adoption rate of mRNA synthesis raw materials has increased among pharma & biotech companies, which further fuels the market growth.
Gather more insights about the market drivers, restrains and growth of the Global mRNA Synthesis Raw Materials Market
Moreover, due to the temporary nature of mRNA translation and lack of integration of the foreign material into the cell's genome, the resulting cellular therapeutic product has a number of benefits over the one obtained by a more conventional approach. Some of the advantages include easier production under acceptable manufacturing procedures, reduced cytotoxicity from on-target off-tumor effects, and better clinical validation and regulatory treatment. Thus, such advantages are expected to increase the demand for mRNA therapeutics and further boost market growth.
Additionally, regarding the treatment and prevention of several diseases, mRNA-based technologies have been proven to be incredibly promising. Tremendous advances in technology and scientific study over the past ten years have made mRNA a feasible therapeutic option, eliminating some of the problems with its use, such as its brief half-life and innate immunogenicity.
mRNA Synthesis Raw Materials Market Report Highlights
• The capping agents segment held the largest share of 39.17% in 2023 owing to the advancements in the capping technology and their applications in the biopharma industry and research
• By application, The vaccine production segment dominated the global industry with the largest revenue share in 2023. This can be attributed to the rapid production of mRNA vaccines compared to the conventional vaccines that utilize cell-culture-based production paths, which are often prone to failure.
• North America dominated the global industry in 2023 and accounted for the largest share of more than 36.77% of the overall revenue in 2023, and is expected to grow at the highest CAGR over the forecast period.
• The biopharmaceutical and pharmaceutical companies segment dominated the market with the highest revenue share in 2023, due to the high commercial success of biopharmaceuticals and rapid growth in demand for therapeutics.
Browse through Grand View Research's Biotechnology Industry Research Reports.
• The global forensic genomics market size was estimated at USD 577.5 million in 2024 and is expected to expand at a CAGR of 14.92% from 2025 to 2030.
• The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.
Segments Covered in the Report
Grand View Research has segmented the global mRNA synthesis raw materials market on the basis of type, application, end-use, and region:
mRNA Synthesis Raw Materials Type Outlook (Revenue, USD Million, 2018 - 2030)
Capping Agents
Nucleotides
Plasmid DNA
Enzymes
Others
DNase
RNase Inhibitor
Polymerase
Others
mRNA Synthesis Raw Materials Application Outlook (Revenue, USD Million, 2018 - 2030)
Vaccine Production
Therapeutics Production
Others
mRNA Synthesis Raw Materials End-use Outlook (Revenue, USD Million, 2018 - 2030)
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Academic & Research Institutes
mRNA Synthesis Raw Materials Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
Order a free sample PDF of the mRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.